Reimbursement to a subject of ancillary costs under the program:

1. (1) does not constitute an inducement to participate in a cancer clinical trial;
2. (2) is not considered coercion or the exertion of undue influence to participate in a cancer clinical trial; and

3. (3) is meant to accomplish parity in access to cancer clinical trials and remove barriers to participation in cancer clinical trials for financially burdened subjects.

   Redesignated by Acts 2021, 87th Leg., R.S., Ch. 915 (H.B. 3607), Sec. 21.001(53), eff. September 1, 2021.

Added by Acts 2019, 86th Leg., R.S., Ch. 1157 (H.B. 3147), Sec. 2, eff. September 1, 2019.